Prostate cancer cells synergistically defend against CD8 (+) T cells by secreting exosomal PD‐L1

BACKGROUND: Metastatic castration‐resistant prostate cancer (mCRPC) remains fatal and incurable, despite a variety of treatments that can delay disease progression and prolong life. Immune checkpoint therapy is a promising treatment. However, emerging evidence suggests that exosomal programmed necro...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Dameng, Zhou, Xueying, Xu, Wenxian, Chen, Yuxin, Mu, Chenglong, Zhao, Xinchun, Yang, Tao, Wang, Gang, Wei, Liang, Ma, Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469662/
https://www.ncbi.nlm.nih.gov/pubmed/37501397
http://dx.doi.org/10.1002/cam4.6275

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469662/
https://www.ncbi.nlm.nih.gov/pubmed/37501397
http://dx.doi.org/10.1002/cam4.6275

Ejemplares similares